Huilin Xu1, Ximing Xu2, Huimin Wang3, Wei Ge4, Dedong Cao5. 1. Department of Oncology, The Fifth Hospital of Wuhan, Xianzheng Road, Hanyang District, Wuhan, Hubei 430000, China. Electronic address: xhlcdd@163.com. 2. Department of Oncology, Renmin Hospital of Wuhan University, Jiefang Road #238 Wuchang District, Wuhan 430000, China. Electronic address: doctorxu120@aliyun.com. 3. Department of Oncology, Yantai Affiliated Hospital of Binzhou Medical University, No. 717 Jinbu Street, Mouping District, Yantai, Shandong, 264100, China. Electronic address: bzwanghuimin@163.com. 4. Department of Oncology, Renmin Hospital of Wuhan University, Jiefang Road #238 Wuchang District, Wuhan 430000, China. Electronic address: gewei514@126.com. 5. Department of Oncology, Renmin Hospital of Wuhan University, Jiefang Road #238 Wuchang District, Wuhan 430000, China. Electronic address: caodedong123@whu.edu.cn.
Abstract
OBJECTIVE: This meta-analysis was to evaluate the impact of antibiotics use on survival of cancer patients with immune checkpoint inhibitors (ICIs). METHODS: Electronic databases including Pubmed, Emabse, and the Cochrane library were searched. The primary endpoints were overall survival (OS) and progression-free survival (PFS). RESULTS: A total of 20 retrospective studies were included. The median OS (7.9 months versus 17.65 months) and PFS (2.4 months versus 4.4 months) of the antibiotics use group were shorter compared to control group. Meta-analysis also showed that the risks of death (HR = 1.90, 95 % CI: 1.55-2.34; P < 0.01) and disease progression (HR=1.53, 95 % CI: 1.30-1.79; P < 0.01) in antibiotics positive group were significantly higher than that of the negative group. The prognostic role of antibiotics use was still significant regardless of cancer types and timing of antibiotics (P < 0.01 for all). CONCLUSION: Use of antibiotics may be associated with worse outcomes in cancer patients treated with ICIs.
OBJECTIVE: This meta-analysis was to evaluate the impact of antibiotics use on survival of cancerpatients with immune checkpoint inhibitors (ICIs). METHODS: Electronic databases including Pubmed, Emabse, and the Cochrane library were searched. The primary endpoints were overall survival (OS) and progression-free survival (PFS). RESULTS: A total of 20 retrospective studies were included. The median OS (7.9 months versus 17.65 months) and PFS (2.4 months versus 4.4 months) of the antibiotics use group were shorter compared to control group. Meta-analysis also showed that the risks of death (HR = 1.90, 95 % CI: 1.55-2.34; P < 0.01) and disease progression (HR=1.53, 95 % CI: 1.30-1.79; P < 0.01) in antibiotics positive group were significantly higher than that of the negative group. The prognostic role of antibiotics use was still significant regardless of cancer types and timing of antibiotics (P < 0.01 for all). CONCLUSION: Use of antibiotics may be associated with worse outcomes in cancerpatients treated with ICIs.